Lurbinectedin in Ewing Sarcoma

AddtoAny
Share:

WATCH THIS PAGE

Subscribe to be notified of changes or updates to this page.

3 + 5 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.

This study involves taking a study drug called lurbinectedin. The overall goal of this study is to see if different doses of lurbinectedin are safe and effective at treating children and young adults with recurrent or relapsed solid tumors, including Ewing Sarcoma.

Who Do I Contact?

If you are interested in participating in the study or want to learn more please contact our study team at CancerTrials [at] chop.edu or 267-425-5544.

Eligibility & Criteria

IRB #:
22-020296
Official Title:
A Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP2D), and Efficacy of Lurbinectedin Monotherapy in Pediatric Participants with Previously Treated Solid Tumors Followed by Expansion to Assess Efficacy and Safety in Pediatric and Young Adult Participants with Relapsed/Refractory Ewing Sarcoma
Study Phase:
Phase I
Phase II
Eligible Age Range:
2 - 30 Years
Gender:
All
Study Categories:

Visit Criteria

As a participant in the research, you will:

  • Receive lurbinectedin infusions
  • Complete frequent clinic visits at CHOP
  • Have frequent blood tests, including research blood tests to measure lurbinectedin levels (pharmacokinetic studies)
  • Have periodic EKGs and echocardiograms
  • Have periodic imaging performed to evaluate your response to treatment
Leader
Theodore W. Laetsch

Theodore Laetsch, MD